HR-4541-119
Placed on the Union Calendar, Calendar No. 650.
Sponsored by Debbie Wasserman Schultz (D-FL)
What it does
This bill would do two things. First, it would extend the EARLY Act — a breast health education program targeting young women — through 2031. Second, it would update and expand the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) by broadening its goals to include prevention and reducing health disparities, streamlining reporting requirements, and authorizing $235.5 million per year in funding for fiscal years 2026 through 2030. It would also require the Government Accountability Office (GAO) to report to Congress by September 2027 on program reach, trends, and barriers to access.
Who benefits
Low-income and uninsured or underinsured women who rely on the NBCCEDP for free or low-cost breast and cervical cancer screenings. Young women who benefit from the EARLY Act's education and awareness programs. Populations with higher-than-average cancer rates, including certain racial and ethnic minority communities, who would be targeted by new disparity-reduction goals. Healthcare navigators and community health workers whose roles are formalized under the expanded support activities. Cancer researchers and public health organizations that receive program funding. States and territories that administer the NBCCEDP grants.
Who is hurt
Federal taxpayers who bear the cost of the $235.5 million annual authorization. Competing federal health programs that may face reduced appropriations if discretionary funding is constrained. Organizations that previously provided case management services, which are removed from the program's explicit list of supported activities, potentially narrowing their funding eligibility. Reporting frequency for Congress is reduced (from annual to every 5 years), which may limit legislative oversight of program performance.
Supporters argue
Supporters argue that breast and cervical cancers remain leading causes of cancer death among women, and that the NBCCEDP has provided screenings to millions of low-income women who would otherwise go unserved — detecting cancers at earlier, more treatable stages. They contend that adding explicit disparity-reduction goals and navigation services addresses documented gaps in screening rates among underserved populations, and that the $235.5 million annual authorization reflects the program's proven track record and growing eligible population.
Opponents argue
Opponents argue that reducing congressional reporting from annual to every five years weakens accountability for a program spending over $1 billion across the authorization window, making it harder to identify and correct underperformance. They contend that the bill's new disparity and equity goals, while broadly worded, lack measurable benchmarks or enforcement mechanisms, and that the funding increase is not tied to demonstrated outcomes — raising questions about whether additional dollars will produce proportional improvements in screening rates or health outcomes.